GGrantIndex
← Leaderboards

George R Washko

Brigham And Women'S Hospital

$16,445,968
Attributed
$41,854,670
Total exposure
10
Grants
7
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $6.4M · FY200725
$10M$7.5M$5M$2.5M$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$41,854,670 · 10

By mechanism

U01$25,153,102 · 1
R01$13,250,338 · 5
T32$2,079,122 · 1
K23$712,800 · 1
U10$481,725 · 1
R03$177,583 · 1

Most similar at Brigham And Women'S Hospital

Same institution · by research overlap

Others in their field

Top investigators on “Lung

Research focus

LungInvestigationBaseChronic Obstructive Airway DiseaseX-Ray Computed TomographyLung DiseasesInsightResearch PersonnelCohortPulmonary EmphysemaImagePhenotypeRespiratory PhysiologyChestClinical ResearchLeadImpairmentPulmonary FunctionFundingEnrollmentAdultScanningSmokerMeasurement

Grant awards (41)

Rheumatoid Arthritis-associated Parenchymal Lung Disease: Clinical and Molecular Phenotypes$736,799
R01 · FY2025 · HL · contact PI
Deep Functional Phenotyping of the ALA Lung Health Cohort$703,387
R01 · FY2025 · HL
Integrated Training in Respiratory Research$453,512
T32 · FY2025 · HL · contact PI
The American Lung Association (ALA) Lung Health Cohort$4,111,293
U01 · FY2024 · HL
Integrated Training in Respiratory Research$828,764
T32 · FY2024 · HL · contact PI
Deep Functional Phenotyping of the ALA Lung Health Cohort$772,943
R01 · FY2024 · HL
Rheumatoid Arthritis-associated Parenchymal Lung Disease: Clinical and Molecular Phenotypes$732,797
R01 · FY2024 · HL · contact PI
The American Lung Association (ALA) Lung Health Cohort$4,746,866
U01 · FY2023 · HL
Integrated Training in Respiratory Research$796,846
T32 · FY2023 · HL · contact PI
Deep Functional Phenotyping of the ALA Lung Health Cohort$691,373
R01 · FY2023 · HL
The American Lung Association (ALA) Lung Health Cohort$4,109,258
U01 · FY2022 · HL
Deep Functional Phenotyping of the ALA Lung Health Cohort$720,972
R01 · FY2022 · HL
The American Lung Association (ALA) Lung Health Cohort$4,192,016
U01 · FY2021 · HL
The clinical impact of longitudinal measures of cardiac and pulmonary vascular morphology in smokers$676,308
R01 · FY2021 · HL · contact PI
The American Lung Association (ALA) Lung Health Cohort$4,726,167
U01 · FY2020 · HL
The clinical impact of longitudinal measures of cardiac and pulmonary vascular morphology in smokers$676,308
R01 · FY2020 · HL · contact PI
The American Lung Association (ALA) Lung Health Cohort$436,313
U01 · FY2020 · HL
The American Lung Association (ALA) Lung Health Cohort$2,831,189
U01 · FY2019 · HL
The clinical impact of longitudinal measures of cardiac and pulmonary vascular morphology in smokers$682,441
R01 · FY2019 · HL · contact PI
The clinical impact of longitudinal measures of cardiac and pulmonary vascular morphology in smokers$728,442
R01 · FY2018 · HL · contact PI
Skeletal muscle, subcutaneous fat, and clinical outcomes in smokers$529,999
R01 · FY2018 · HL · contact PI
Skeletal muscle, subcutaneous fat, and clinical outcomes in smokers$530,784
R01 · FY2017 · HL · contact PI
The clinical impact of pulmonary vascular remodeling in smokers$436,210
R01 · FY2017 · HL · contact PI
Skeletal muscle, subcutaneous fat, and clinical outcomes in smokers$527,452
R01 · FY2016 · HL · contact PI
The clinical impact of pulmonary vascular remodeling in smokers$436,358
R01 · FY2016 · HL · contact PI
Skeletal muscle, subcutaneous fat, and clinical outcomes in smokers$545,234
R01 · FY2015 · HL · contact PI
The clinical impact of pulmonary vascular remodeling in smokers$462,911
R01 · FY2015 · HL · contact PI
The clinical impact of pulmonary vascular remodeling in smokers$454,695
R01 · FY2014 · HL · contact PI
Computed Tomographic characterization of subjects enrolled in the STATCOPE trial$433,756
R01 · FY2014 · HL · contact PI
The clinical impact of pulmonary vascular remodeling in smokers$474,764
R01 · FY2013 · HL · contact PI
Computed Tomographic characterization of subjects enrolled in the STATCOPE trial$413,585
R01 · FY2013 · HL · contact PI
Computed Tomographic characterization of subjects enrolled in the STATCOPE trial$432,089
R01 · FY2012 · HL · contact PI
Using Computed Tomographic Imaging as a biomarker for Clinical COPD Research$142,560
K23 · FY2012 · HL · contact PI
Computed Tomographic characterization of subjects enrolled in the STATCOPE Invest$450,731
R01 · FY2011 · HL · contact PI
Using Computed Tomographic Imaging as a biomarker for Clinical COPD Research$142,560
K23 · FY2011 · HL · contact PI
Using Computed Tomographic Imaging as a biomarker for Clinical COPD Research$142,560
K23 · FY2010 · HL · contact PI
Autophagy in COPD$89,000
R03 · FY2010 · HL
Using Computed Tomographic Imaging as a biomarker for Clinical COPD Research$142,560
K23 · FY2009 · HL · contact PI
Autophagy in COPD$88,583
R03 · FY2009 · HL
Using Computed Tomographic Imaging as a biomarker for Clinical COPD Research$142,560
K23 · FY2008 · HL · contact PI
COPD Exacerbations: Pharmacogenetic Approaches to Therapy$481,725
U10 · FY2007 · HL · contact PI